ARQ 197 in Subjects With Metastatic Solid Tumors

Inclusion Criteria

• •Signed written informed consent must be obtained and documented according to ICH GCP, the local regulatory requirements, and permission to use private health information in accordance with HIPPA prior to study-specific screening procedures
• •A histologically or cytologically confirmed RCC or other c-Met expression tumors that is metastatic
• •Patient must have available archival tumor tissue or accessible tumor that is safely amenable to tumor biopsy
• •≥ 18 years of age
• •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
• •Karnofsky performance status ≥ 70%
• •Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last ARQ 197 dose
• •Females of childbearing potential must have a negative serum pregnancy test
• •Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5.0 × ULN with metastatic liver disease.
• •Hemoglobin (Hgb) ≥ 10 g/dl
• •Total bilirubin ≤ 1.5 × ULN
• •Creatinine ≤ 1.5 x ULN
• •Absolute neutrophil count ≥ 1.5 x 10\^9/L
• •Platelets ≥ 100 x 10\^9/L